you are such a liar. you pick the high of the stock on any given day and proclaim at the end of trading that you somewhat timed that high exactly and went short the stock at that point. Such BS. you lost money on your last short - and everyone knows that because it was at 11.55 and the stock blew through that on upside.
worth more than that - the number of employees is irrelevant here. it's the value of the clinical candidates once all the data is reported. If the data flow continues to be positive, TGTX is worth at least 30 in a buyout - and possibly more once ph III reads out
I think he was actually a short. I've seen them crop up in biotech stocks that they target as potentially movable w/ a lot of bashing. I thought this stock was not a good one for that strategy, and my guess is that he ended up with a loss. I haven't a peep from him since TGTX started to move up.
For ibrutinib + 1101, if the data (w/ additional patients not reflected in the ASH abstract) continues to show over 90% ORR and no indication of antagonism of ADCC via the ibrutinib mechanism, that would be very positive going into ph. III. Also, if they report some data from the ongoing ibrutinib + 1101 + 1202 trial, and it looks positive with no indication of undue toxicity (as has been seen with idelasib in complex combination trials), then that would be extra positive. Then add more positive data related to 1101 + 1202 trial and the 1202 monotherapy trial. If all the foregoing, then i'd say close to 15.
i'm not really bothered by it. I just think that Weiss is a good CEO from an investor perspective - he seems focused on a quick path to approval, he maintains a very large stake in the company, and he has, thus far, tried to avoid serial secondary offerings. I own MACK as well - and the CEO of that company seems a bit more academic or research oriented, and less focused on investor interests. But even if another CEO is appointed for TGTX, i think Weiss will remain a strong force at the company (probably at the Board level)
The other two things that i noted from the conference call: 1) Weiss is an "interim" CEO. i didn't appreciate this - i think he is very focused on the share price and efficiency, so i assume he'll remain deeply involved even if a permanent CEO is appointed. 2) there is an interest in pursuing 1101 and 1202, alone or together, in autoimmune diseases, such as rheumatoid arthritis and lupus. This is great, but Weiss was clear that these trials probably wouldn't get going until end of 2015 at earliest (which is fine - many, many useful ideas in the oncology setting).
It was positive in general. A few issues: 1) Weiss seemed to suggest that as more patients are added, the ORR for ibrutinib/1101 in the refractory CLL setting will drop slightly from 94% to about 90% or 90% plus 1-2% but this remains well ahead of ibrutinib alone which is around 55-70% in this setting; 2) ibrutinib + 1101 + 1202 is still ongoing but not many patients in the study at present. There has been recent reports of tox issues when combining idelasib in complex combinations like this, but those tox issues have not emerged thus far in this particular trial (but it's early days). it appears they will report preliminary data from this - or at least on the status - at ASH; 3) there will be an analyst meeting at ASH and investors will be able to dial into that.
you are probably right about RA Capital. Going it alone would be tough - they don't have the infrastructure, experience, etc to manufacture, pursue registration in multiple jurisdictions, and market these two drugs - i think the ultimate goal here is to partner or pursue a buyout, but at the right price point for Weiss - which is at a much higher stock price (given how much of a personal financial stake he has in this company)
I think it was generally positive, but i think the stock will dip tomorrow. MACK has alot of viable, strong clinical drugs and programs but is run somewhat like a Kendall Square research organization and less like a biotech focused on getting the stock price up. I continue to hold thousands of shares but do agree with those who view the salaries as a bit rich. I prefer to keep salaries a bit tight and align incentives with stock appreciation.
enough to fund existing trials, including the 1101 ph III, and out to mid-2016 is my bet. Might be trying to build a cash runway to NDA filing. We'll know tomorrow morning.
And remember - these are pretreated, generally heavily pretreated, patients. The ORR is great considering that. Can't wait to hear more tomorrow. And 1202 is doing great too.
and how is that short position working for you now? i told you it was an unwise short - INFI is not an analogous stock, the market cap for that was hugely higher than TGTX's when it fell, and it's drug had potential tox issues.
it's possible they might go it alone in completing the SPA-driven ph III with 1101/ibrutinib (since that trial is so manageable in size), but i can see a strong rationale in partnering the phase III for 1202 because it might make sense to pursue multiple, parallel trials given the large number of potential combinations with 1202. A buyout at this point is always possible as well, particularly after ASH since the data pool for 1101 and 1202 will be that much more significant (thus de-risking the clinical profile for 1101 and 1202 in the eyes of a potential acquirer).
he claims to have shorted below 11 as well - and that position is now a negative bet. He's just a weird foreigner (you can tell by his english usage). It's obvious that TGTX is not going to do some sort of big swing down given the continued positive data from their ongoing trials and the relatively low market cap of the company. So it's a stupid strategy to short it. There are much better "bubble" stocks out there.
And Abstract 4486 adds to this theme. This study focused on the combination of TGR-1202 with brentuximab (BV)(idelasib was not studied) and found a synergistic effect for TGR-1202 + BV. Here are the results: The novel PI3K-δ inhibitor TGR-1202 synergistically enhances the anti-tumor activity of BV by increasing drug-induced cell death and tubulin disruption in HL cell line xenografts. These data provide a strong rationale for clinical studies using TGR-1202/BV in combination in refractory/relapsed HL patients. A Phase I study of the combination of TGR-1202 and BV is ongoing in patients with relapsed/refractory HL.